<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39460254</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>24</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>Formulation Attributes Impact Immune Profile of an Oral and Thermostable COVID-19 Subunit Vaccine.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1087</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines12101087</ELocationID><Abstract><AbstractText>While approved vaccines for COVID-19 provide protection against severe disease and death, they have limited efficacy in the prevention of infection and virus transmission. Mucosal immunity is preferred over systemic immunity to provide protection at the point of entry against pathogens such as SARS-CoV-2. VaxForm has developed an oral vaccine delivery platform that elicits mucosal and systemic immune responses by targeting immune cells in the gut through C-type lectin receptors. The technology consists of microencapsulating the vaccine with an enteric polymer, which also results in enhanced thermostability. This article describes the formulation development and in vivo testing of a novel protein-based oral COVID-19 vaccine using this technology. Results demonstrate successful induction of immune response in mice and showed that the particle size of the vaccines following administration can impact the ratio of mucosal to systemic response. Immunogenicity and thermostability of liquid suspension and dry powder versions of the vaccine were compared in mice. The liquid suspension vaccine showed excellent heat resistance by maintaining immunogenicity after 14 days of storage at 60 °C. While further investigation is needed to determine correlates of protection and duration of response for mucosal immunity, this study demonstrates the vaccine's potential as a COVID-19 booster to enhance mucosal protection in humans and improve global access by lowering the cost of production, removing cold-chain requirements, and allowing self-administration.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Burlet</LastName><ForeName>Elodie</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>VaxForm, LLC., Bethlehem, PA 18015, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>Nissy</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>VaxForm, LLC., Bethlehem, PA 18015, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carwell</LastName><ForeName>Shanna</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>VaxForm, LLC., Bethlehem, PA 18015, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gershman</LastName><ForeName>Brett W</ForeName><Initials>BW</Initials><Identifier Source="ORCID">0000-0002-2130-6792</Identifier><AffiliationInfo><Affiliation>VaxForm, LLC., Bethlehem, PA 18015, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morefield</LastName><ForeName>Garry L</ForeName><Initials>GL</Initials><AffiliationInfo><Affiliation>VaxForm, LLC., Bethlehem, PA 18015, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2031281</GrantID><Agency>National Science Foundation</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19 vaccine</Keyword><Keyword MajorTopicYN="N">mucosal immunity</Keyword><Keyword MajorTopicYN="N">oral subunit vaccine</Keyword><Keyword MajorTopicYN="N">powder vaccine</Keyword><Keyword MajorTopicYN="N">thermostable vaccine</Keyword></KeywordList><CoiStatement>Authors Elodie Burlet, Nissy Thomas, and Garry Morefield are employed by VaxForm, LLC. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39460254</ArticleId><ArticleId IdType="pmc">PMC11511547</ArticleId><ArticleId IdType="doi">10.3390/vaccines12101087</ArticleId><ArticleId IdType="pii">vaccines12101087</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>WHO  COVID Tracker.  [(accessed on 10 July 2024)];2020  Available online:  https://covid19.who.int/</Citation></Reference><Reference><Citation>Neutra M.R., Kozlowski P.A. Mucosal vaccines: The promise and the challenge. Nat. Rev. Immunol. 2006;6:148–158. doi: 10.1038/nri1777.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri1777</ArticleId><ArticleId IdType="pubmed">16491139</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavelle E.C., Ward R.W. Mucosal vaccines—Fortifying the frontiers. Nat. Rev. Immunol. 2022;22:236–250. doi: 10.1038/s41577-021-00583-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-021-00583-2</ArticleId><ArticleId IdType="pmc">PMC8312369</ArticleId><ArticleId IdType="pubmed">34312520</ArticleId></ArticleIdList></Reference><Reference><Citation>Mutsch M., Zhou W., Rhodes P., Bopp M., Chen R.T., Linder T., Spyr C., Steffen R. Use of the Inactivated Intranasal Influenza Vaccine and the Risk of Bell’s Palsy in Switzerland. N. Engl. J. Med. 2004;350:896–903. doi: 10.1056/NEJMoa030595.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa030595</ArticleId><ArticleId IdType="pubmed">14985487</ArticleId></ArticleIdList></Reference><Reference><Citation>Helander H.F., Fändriks L. Surface area of the digestive tract—Revisited. Scand. J. Gastroenterol. 2014;49:681–689. doi: 10.3109/00365521.2014.898326.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/00365521.2014.898326</ArticleId><ArticleId IdType="pubmed">24694282</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen K., Cerutti A. Vaccination Strategies to Promote Mucosal Antibody Responses. Immunity. 2010;33:479–491. doi: 10.1016/j.immuni.2010.09.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2010.09.013</ArticleId><ArticleId IdType="pmc">PMC3045856</ArticleId><ArticleId IdType="pubmed">21029959</ArticleId></ArticleIdList></Reference><Reference><Citation>Hase K., Kawano K., Nochi T., Pontes G.S., Fukuda S., Ebisawa M., Kadokura K., Tobe T., Fujimura Y., Kawano S., et al. Uptake through glycoprotein 2 of FimH+ bacteria by M cells initiates mucosal immune response. Nature. 2009;462:226–230. doi: 10.1038/nature08529.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature08529</ArticleId><ArticleId IdType="pubmed">19907495</ArticleId></ArticleIdList></Reference><Reference><Citation>Geijtenbeek T.B.H., Gringhuis S.I. Signalling through C-type lectin receptors: Shaping immune responses. Nat. Rev. Immunol. 2009;9:465–479. doi: 10.1038/nri2569.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2569</ArticleId><ArticleId IdType="pmc">PMC7097056</ArticleId><ArticleId IdType="pubmed">19521399</ArticleId></ArticleIdList></Reference><Reference><Citation>Ermak T.H., Giannasca P.J. Microparticle targeting to M cells. Adv. Drug Deliv. Rev. 1998;34:261–283. doi: 10.1016/S0169-409X(98)00043-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0169-409X(98)00043-X</ArticleId><ArticleId IdType="pubmed">10837681</ArticleId></ArticleIdList></Reference><Reference><Citation>Morefield G.L., Sokolovska A., Jiang D., HogenEsch H., Robinson J.P., Hem S.L. Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro. Vaccine. 2005;23:1588–1595. doi: 10.1016/j.vaccine.2004.07.050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2004.07.050</ArticleId><ArticleId IdType="pubmed">15694511</ArticleId></ArticleIdList></Reference><Reference><Citation>Du L., Zhao G., Chan C.C.S., Sun S., Chen M., Liu Z., Guo H., He Y., Zhou Y., Zheng B.-J., et al. Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity. Virology. 2009;393:144–150. doi: 10.1016/j.virol.2009.07.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2009.07.018</ArticleId><ArticleId IdType="pmc">PMC2753736</ArticleId><ArticleId IdType="pubmed">19683779</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng K., Pouniotis D.S., Wright M.D., Tang C.K., Lazoura E., Pietersz G.A., Apostolopoulos V. Mannan derivatives induce phenotypic and functional maturation of mouse dendritic cells. Immunology. 2006;118:372–383. doi: 10.1111/j.1365-2567.2006.02384.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2567.2006.02384.x</ArticleId><ArticleId IdType="pmc">PMC1782308</ArticleId><ArticleId IdType="pubmed">16827898</ArticleId></ArticleIdList></Reference><Reference><Citation>Eldridge J.H., Meulbroek J.A., Staas J.K., Tice T.R., Gilley R.M. Vaccine-containing biodegradable microspheres specifically enter the gut-associated lymphoid tissue following oral administration and induce a disseminated mucosal immune response. Adv. Exp. Med. Biol. 1989;251:191–202. doi: 10.1007/978-1-4757-2046-4_18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4757-2046-4_18</ArticleId><ArticleId IdType="pubmed">2610110</ArticleId></ArticleIdList></Reference><Reference><Citation>Eldridge J.H., Gilley R., Staas J.K., Moldoveanu Z., Meulbroek J.A., Tice T.R. Biodegradable microspheres: Vaccine delivery system for oral immunization. Curr. Top. Microbiol. Immunol. 1989;146:59–66. doi: 10.1007/978-3-642-74529-4_6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-642-74529-4_6</ArticleId><ArticleId IdType="pubmed">2731430</ArticleId></ArticleIdList></Reference><Reference><Citation>Knisely J.M., Buyon L.E., Mandt R., Farkas R., Balasingam S., Bok K., Buchholz U.J., D’souza M.P., Gordon J.L., King D.F.L., et al. Mucosal vaccines for SARS-CoV-2: Scientific gaps and opportunities—Workshop report. Vaccines. 2023;8:53. doi: 10.1038/s41541-023-00654-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-023-00654-6</ArticleId><ArticleId IdType="pmc">PMC10091310</ArticleId><ArticleId IdType="pubmed">37045860</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker J.R., Farazuddin M., Wong P.T., O’konek J.J. The unfulfilled potential of mucosal immunization. J. Allergy Clin. Immunol. 2022;150:1–11. doi: 10.1016/j.jaci.2022.05.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2022.05.002</ArticleId><ArticleId IdType="pmc">PMC9098804</ArticleId><ArticleId IdType="pubmed">35569567</ArticleId></ArticleIdList></Reference><Reference><Citation>Negi N., Maurya S.P., Singh R., Das B.K. An update on host immunity correlates and prospects of re-infection in COVID-19. Int. Rev. Immunol. 2021;41:367–392. doi: 10.1080/08830185.2021.2019727.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08830185.2021.2019727</ArticleId><ArticleId IdType="pmc">PMC8787841</ArticleId><ArticleId IdType="pubmed">34961403</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallo O., Locatello L.G., Mazzoni A., Novelli L., Annunziato F. The central role of the nasal microenvironment in the transmission, modulation, and clinical progression of SARS-CoV-2 infection. Mucosal Immunol. 2021;14:305–316. doi: 10.1038/s41385-020-00359-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41385-020-00359-2</ArticleId><ArticleId IdType="pmc">PMC7690066</ArticleId><ArticleId IdType="pubmed">33244161</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z., Lorenzi J.C.C., Muecksch F., Finkin S., Viant C., Gaebler C., Cipolla M., Hoffmann H.-H., Oliveira T.Y., Oren D.A., et al. Enhanced SARS-CoV-2 neutralization by dimeric IgA. Sci. Transl. Med. 2021;13:abf1555. doi: 10.1126/scitranslmed.abf1555.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abf1555</ArticleId><ArticleId IdType="pmc">PMC7857415</ArticleId><ArticleId IdType="pubmed">33288661</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojas O.L., Pröbstel A.-K., Porfilio E.A., Wang A.A., Charabati M., Sun T., Lee D.S., Galicia G., Ramaglia V., Ward L.A., et al. Recirculating Intestinal IgA-Producing Cells Regulate Neuroinflammation via IL-10. Cell. 2019;177:492–493. doi: 10.1016/j.cell.2019.03.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2019.03.037</ArticleId><ArticleId IdType="pubmed">30951673</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh S., Singh G., Arya S.K. Mannans: An overview of properties and application in food products. Int. J. Biol. Macromol. 2018;119:79–95. doi: 10.1016/j.ijbiomac.2018.07.130.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijbiomac.2018.07.130</ArticleId><ArticleId IdType="pubmed">30048723</ArticleId></ArticleIdList></Reference><Reference><Citation>Shon N.N., Yarbrough T., Patel P. Aluminum Hydroxide. StatPearls Publishing; Treasure Island, FL, USA: 2023.</Citation><ArticleIdList><ArticleId IdType="pubmed">31536275</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>